GlassScriptPhysician profile
Douglas Y Chan
NPI 1548558984
$3,614.34
in general payments reported to CMS, 2019-2025
21 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 90% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $545 · 2024: $1,681 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,614.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $784.81 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $539.24 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $409.62 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Otsuka America Pharmaceutical, INC. | $270.19 | 2023-2025 | Rexulti |
| Lundbeck LLC | $233.39 | 2023-2025 | Rexulti |
| Bausch Health US, LLC | $196.67 | 2024-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $190.60 | 2024-2025 | Spravato |
| Corium, LLC | $166.62 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $139.94 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $135.62 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $108.84 | 2023-2025 | Trintellix |
| Abbvie INC. | $85.57 | 2023-2025 | Vraylar |
| Idorsia Pharmaceuticals US INC | $70.49 | 2023-2024 | Quviviq |
| Noven Therapeutics, LLC | $68.62 | 2024-2025 | Xelstrym |
| Brainsway USA INC | $42.89 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $42.57 | 2023-2024 | Austedo Xr |
| Noven Pharmaceuticals, INC. | $36.80 | 2023-2024 | Xelstrym |
| Axsome Therapeutics, INC. | $33.26 | 2023 | Auvelity |
| Tempus Ai, INC | $24.04 | 2024 | |
| Neos Therapeutics, LP | $17.34 | 2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $17.22 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.